These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38699313)

  • 21. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023.
    Jeworowski LM; Mühlemann B; Walper F; Schmidt ML; Jansen J; Krumbholz A; Simon-Lorière E; Jones TC; Corman VM; Drosten C
    Euro Surveill; 2024 Jan; 29(2):. PubMed ID: 38214083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia.
    Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S
    J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
    Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.
    Lu Y; Ao D; He X; Wei X
    MedComm (2020); 2024 Aug; 5(8):e675. PubMed ID: 39081516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.
    Li L; Shi K; Gu Y; Xu Z; Shu C; Li D; Sun J; Cong M; Li X; Zhao X; Yu G; Hu S; Tan H; Qi J; Ma X; Liu K; Gao GF
    Structure; 2024 Aug; 32(8):1055-1067.e6. PubMed ID: 39013463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
    Arantes I; Gomes M; Ito K; Sarafim S; Gräf T; Miyajima F; Khouri R; de Carvalho FC; de Almeida WAF; Siqueira MM; Resende PC; Naveca FG; Bello G;
    Microbiol Spectr; 2024 Mar; 12(3):e0383123. PubMed ID: 38315011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.
    Gayed J; Bangad V; Xu X; Mensa F; Cutler M; Türeci Ö; Şahin U; Modjarrad K; Swanson KA; Anderson AS; Gurtman A; Kitchin N;
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages.
    Barrera A; Martínez-Valdebenito C; Angulo J; Palma C; Hormazábal J; Vial C; Aguilera X; Castillo-Torres P; Pardo-Roa C; Balcells ME; Nervi B; Corre NL; Ferrés M
    Front Med (Lausanne); 2024; 11():1414331. PubMed ID: 39267969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
    Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JN.1: enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022.
    Du P; Li M; Wei G; Guo C; Li N
    Front Public Health; 2024; 12():1442291. PubMed ID: 39391153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.